EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease

Summary

A Phase 1, 2-part, multicentre study to evaluate the safety and preliminary efficacy of the oral administration of EXL01 in the maintenance of corticosteroid-induced clinical response/remission in participants with mild to moderate Crohn's Disease (CD).

Timeline

Start

2023-03-20

Primary completion

2024-10-02

Completion

2024-10-02

Publications

• Guarino-Vignon P, Louis E, Pham HP, Orianne G, Tkacz E, Brot L, Mazzetti E, Sedda D, Ruffie P, Rolhion N, D'Haens G, Hadida B, Langella P, Sokol H. Faecalibacterium prausnitzii EXL01 for the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Crohn's Disease: a first in human trial. Nat Commun. 2026 Apr 28. doi: 10.1038/s41467-026-72375-y. Online ahead of print.

Drugs

Indications